The European Medicines Agency (EMA) declares that it is investigating a possible angle of the AstraZeneca antiviral vaccine with a habitual problem of vascular vesicles, as well as a possible relationship between the Johnson & Johnson vesicle and blood clots.
Through the detection of sanguine thrombi that provoked outrage in the wake of AstraZeneca, the EMA now examines five cases of denominated capillary fugue syndrome, characterized by a “fluid surge in blood vessels, which causes inflammation”.
The European Union’s drug regulator has also released the woman who initiated an examination of possible lesions between the vaccine against the Johnson & Johnson coronavirus and coagulated glands through the information of four cases, one of them mortal.
“Several serious cases of unusual blood clots were reported with a level of plaques following the Janssen vaccination against covid-19”, the EMA said, referring to the European branch of the pharmaceutical giant Estadounidense.
“Todavía is not clear if there is a causal relationship” between the administration of the vacancies and the secondary effects quoted, said notwithstanding the EMA, based in Amsterdam, in a communication.
The EMA states that it analyzes the information relative to these possible secondary effects of AstraZeneca and J&J “decides whether it is necessary to adopt regulatory means”, which generally consist of aggregating notifications regarding secondary effects.